Zepp Health Corp

Zepp Health Corp (ZEPP) Stock Analysis

$3.020

-0.170 (-5.63%)At close

Loading chart…
High
3.300
Open
3.230
VWAP
3.10
Volume
36.29K
Mkt Cap
35.99M
Low
2.980
Amount
112.50K
EV/EBITDA, TTM
-2.40

Zepp Health Corp, formerly Huami Corp, is a Netherlands-based company primarily engaged in the consumer electronics and digital health technology industry. The Company focuses on developing smart wearable devices and digital health management platforms. Their key product is the Zepp Digital Health Management Platform, which is a cloud-based system integrating smart devices, biometric sensors, Artificial Intelligence (AI) chips, and data algorithms. It aims to provide users with 24/7 actionable insights to support health, fitness, and wellness management. The platform powers a range of products including smartwatches, fitness bands, smart rings, and hearables under the Amazfit and Zepp brand names. Additionally, the Company offers AI-driven services such as Zepp Aura for sound-based wellness and Zepp Clarity for hearing health. The Company has one reportable segment: Amazfit-branded products.

www.huami.com

AI analysis of Zepp Health Corp (ZEPP)

Sell

Zepp Health Corp is not a good buy right now due to a current price of $3.02 and a concerning RSI of 5.838, indicating extreme oversold conditions. The company has reported a staggering year-to-date change of -89.23% and a one-year change of -93.94%, reflecting severe financial distress. Additionally, the forward P/E ratio stands at 3.124, which may seem low but is overshadowed by the company's ongoing net losses, including a net loss of $11.33 million in Q2 2026. The main risk is the widening operating loss and declining revenue expectations for Q3 2026, which could further impact stock performance.

Valuation Metrics

The current forward P/E ratio for Zepp Health Corp (ZEPP) is 3.12, compared to its 5-year average forward P/E of -38.25.

Forward P/E

Fair
5Y Average P/E
-38.25
Current P/E
3.12
Overvalued
83.62
Undervalued
-160.12

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-11.66
Current EV/EBITDA
-2.40
Overvalued
22.17
Undervalued
-45.49

Forward P/S

Fair
5Y Average P/S
0.37
Current P/S
0.02
Overvalued
0.96
Undervalued
-0.22

Whales holding ZEPP

T

Trivest Advisors Ltd

+ HoldingZEPP

-12.96%

3M Return

Events Timeline

2026-09-22 (ET)

07:30:00

Amazfit Launches T-Rex Dual Solar Smartwatch at $649.99

2026-06-08 (ET)

21:40:00

Q1 Revenue Reaches $51.5 Million

2026-05-13 (ET)

07:30:00

Amazfit Launches Cheetah 2 Ultra at $599.99

2026-04-16 (ET)

07:10:00

Amazfit Launches Cheetah 2 Pro Sports Watch at $449.99

2026-04-15 (ET)

07:10:00

Zepp Health Signs Three-Year Global Partnership with HYROX

News

ZEPP FAQ — answered by Alphio AI

Zepp Health Corp, formerly Huami Corp, is a Netherlands-based company primarily engaged in the consumer electronics and digital health technology industry. The Company focuses on developing smart wearable devices and digital health management platforms. Their key product is the Zepp Digital Health Management Platform, which is a cloud-based system integrating smart devices, biometric sensors, Artificial Intelligence (AI) chips, and data algorithms. It aims to provide users with 24/7 actionable insights to support health, fitness, and wellness management. The platform powers a range of products including smartwatches, fitness bands, smart rings, and hearables under the Amazfit and Zepp brand names. Additionally, the Company offers AI-driven services such as Zepp Aura for sound-based wellness and Zepp Clarity for hearing health. The Company has one reportable segment: Amazfit-branded products. It operates in the Technology sector (ELECTRONIC COMPUTERS industry).

Zepp Health Corp is not a good buy right now due to a current price of $3.02 and a concerning RSI of 5.838, indicating extreme oversold conditions. The company has reported a staggering year-to-date change of -89.23% and a one-year change of -93.94%, reflecting severe financial distress. Additionally, the forward P/E ratio stands at 3.124, which may seem low but is overshadowed by the company's ongoing net losses, including a net loss of $11.33 million in Q2 2026. The main risk is the widening operating loss and declining revenue expectations for Q3 2026, which could further impact stock performance.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading